Christopher E Hopkins, PhD, MBA

Experience

• 

  University of Utah

  Jan 1987 - Jan 1996

  Chris worked in Dr Raymond Gesteland lab to develop ESI mass spec polymorphism analysis Chris worked with Dr. Tom Alber to perform studies on circularly permuted lysozyme. In Dr. Toto Olivera lab at U of Utah, Chris invented snail milking technique used to isolation of conotoxin neuropeptides.

  • Research Associate

    Jan 1992 - Jan 1996

  • Research Technician

    Jan 1991 - Jan 1992

  • Research Technician

    Jan 1987 - Jan 1991
• 

  Hybridon, Inc

  Jan 1996 - Jan 1997

  Research Associate

  Chris worked with Dr. Bing Wang to developed novel oligonucleotide sequencing methodology at antisense therapeutics company

• 

  Boston University

  Jan 1997 - Jan 2002

  Graduate degree

  In Dr Dean Tolan Lab, Chris combined Mass Spec, NMR, and X-ray studies with chemical modification rescue experiments to dissect molecular mechanism of Aldolase function.

• 

  University of Utah

  Jan 2003 - Jan 2010

  Post Docorate

  Chris worked with Dr Erik Jorgensen and Dr Christan Frokjaer-Jensen in the development MosSCI transgenesis technology.

• 

  Knudra Transgenics

  Jan 2009 - Jan 2017

  Founder and Chief Science Officer

  Knudra Transgenics provided Genomes Built to Spec which created customized transgenics in C. elegans and zebrafish. As founder, Chris harnessed a passion for advancing medical discovery into a first-in-kind service for the C. elegans and zebrafish research community. Chris helped pioneer the adoption of CRISPR-editing into multiple research lab workflows. Knudra Transgenics was acquired by NemaMetrix (now InVivo Biosystems) in late 2017. Chris retained his role as CSO.

• 

  AxumBio

  Mar 2012 - Jul 2017

  Founder

  Axumbio developed discovery platforms for finding novel anti-parasite drugs. Chris pioneered the use of genome engineering techniques create new discovery systems expressing specific parasite genes.

• 

  InVivo Biosystems

  Jan 2017 - Jan 2024

  Chief Science Officer

  In Vivo Biosystems is a platform drug discovery company with an innovative pipeline in CNS, metabolic, cardio and cancer portfolios. In the role as Chief Science Officer, Chris facilitates market adoption of these proprietary systems into pharma, biotech and related industries. The role includes new product innovation, market outreach, business development, and strategic planning.

• 

  Devinebio

  Jan 2020 - now

  Founder

  Devinebio partners with emerging foundations and companies in the biotech space to find genetic medicines to develop as treatment for their rare disease. We help Patient Advocacy Groups (PAGs) and new biotechs develop strategies that get them from target to IND enabled, which is often a key value inflection that gets the attention of big Pharma. We first focus on drug repurposing and then biologics (ASO and AAV) as the fastest route to getting these needed treatments into the marketplace.

• 

  CureCADASIL

  Jan 2022 - now

  SAB member

  As a member of the SAB at cureCADASIL, Chris used his experience in entrepreneurship in biochemistry and genetics to help found the CADASIL Disease Modeling Group (CDMG). The group brings together leading vascular biology researchers with the bold 5 step mission: 1) Create a USA-based aggregate patient registry within 1 year, 2) Deploy omics technologies to help understand disease mechanisms and reveal biomarkers within 1 year, 3) Obtain CADASIL-related grant funding within 1 year, 4) Help train and build the community, and hold a research symposium within 2 years,5) Create model systems built so biomarker conservation can be assessed and high-throughput drug screens performed within 3 years. Exibir menos

• 

  Glafabra Therapeutics

  Jan 2024 - now

  Chief Executive Officer

  At Glafabra Therapeutics we are building durable cell therapies for enzyme deficiency disorders that effect 80M patients worldwide. Our lead asset GT-GLA-S03 is in Fabry disease ant its therapeutic durability is now well documented in publications of Canadian clinical trials. Other diseases targets in metabolic disorders are under development using our STEM, TRAM and iTRAM technologies.